| Literature DB >> 18606776 |
Nikos Vasilakis1, Anna P Durbin, Amelia P A Travassos da Rosa, Jorge L Munoz-Jordan, Robert B Tesh, Scott C Weaver.
Abstract
Sylvatic dengue viruses (DENVs) are transmitted between non-human primates and arboreal Aedes spp. mosquitoes in Southeast Asia and west Africa. Recent evidence suggests that the risk for re-emergence of sylvatic DENV into the urban endemic/epidemic cycle may be high, which could limit the potential for eradicating the human transmission cycle with vaccines now under development. We assessed the likelihood of sylvatic DENV re-emergence in the face of immunity to current endemic strains or vaccines by evaluating the neutralization capacity of sera from DENV vaccinees and convalescent patients after primary infection with DENV-2 and DENV-3 serotypes. Our data indicate robust homotypic cross-immunity between human sera and sylvatic DENV strains, but limited heterotypic neutralization. Should a licensed vaccine lead to the eradication of the urban transmission cycle in the future, re-emergence of sylvatic strains into the urban cycle would be limited by homotypic immunity mediated by virus-neutralizing antibodies.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18606776
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 2.345